Search research articles
Contact Us
Filters
Showing results (1-10 of 17) with videos related to
Page
of 2
Sort By:
Chemical Research in Toxicology
|
February 19, 2002
Inhibition of cell proliferation and AP-1 activity by acrolein in human A549 lung adenocarcinoma cells due to thiol imbalance and covalent modifications
Shyam Biswal, George Acquaah-Mensah, Kaushik Datta, et al.
Applied Optics
|
March 16, 2019
Computational requirements for real-time ptychographic image reconstruction
Kaushik Datta, Andrew Rittenbach, Dong-In Kang, et al.
Chemical Research in Toxicology
|
November 16, 2007
Metabonomic evaluation of metabolic dysregulation in rats induced by PF 376304, a novel inhibitor of phosphoinositide 3-kinase
Donald G Robertson, Kaushik Datta, Dale Wells, et al.
Regulatory Toxicology and Pharmacology : RTP
|
July 20, 2025
Strategies to reduce the use of non-human primates in the development of oncology therapeutics: CD3-bispecifics
Smitha Ps Pillai, Kaushik Datta, Petra Lutterbuese, et al.
Regulatory Toxicology and Pharmacology : RTP
|
February 21, 2021
Harmonized 3Rs-based non-mutagenic impurity qualification study designs developed using the results of an IQ consortium survey
Mayur S Mitra, Kaushik Datta, Richard Hutchinson, et al.
Clinical Pharmacology and Therapeutics
|
June 7, 2024
Beyond MABEL: An Integrative Approach to First in Human Dose Selection of Immunomodulators by the Health and Environmental Sciences Institute (HESI) Immuno-Safety Technical Committee (ITC)
Mineo Matsumoto, Joseph Ryan Polli, Suresh K Swaminathan, et al.
Regulatory Toxicology and Pharmacology : RTP
|
February 1, 2026
FIH Dose Selection Beyond MABEL: Optimizing Phase 1 clinical trial Starting Dose Whilst Protecting Patient Safety
Mineo Matsumoto, J Ryan Polli, Suresh Swaminathan, et al.
Journal of Medicinal Chemistry
|
May 14, 2010
Rational design of a topical androgen receptor antagonist for the suppression of sebum production with properties suitable for follicular delivery
Lorna H Mitchell, Theodore R Johnson, Guang Wei Lu, et al.
Toxicology
|
July 3, 2015
Importance of investigating epigenetic alterations for industry and regulators: An appraisal of current efforts by the Health and Environmental Sciences Institute
Isabelle R Miousse, Richard Currie, Kaushik Datta, et al.
Clinical Pharmacology and Therapeutics
|
September 19, 2024
Industry Perspective on First-in-Human and Clinical Pharmacology Strategies to Support Clinical Development of T-Cell Engaging Bispecific Antibodies for Cancer Therapy
Prathap Nagaraja Shastri, Nirav Shah, Martin Lechmann, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 17) with videos related to
Sort By:
Page
of 2
Chemical Research in Toxicology
|
February 19, 2002
Inhibition of cell proliferation and AP-1 activity by acrolein in human A549 lung adenocarcinoma cells due to thiol imbalance and covalent modifications
Shyam Biswal, George Acquaah-Mensah, Kaushik Datta, et al.
Applied Optics
|
March 16, 2019
Computational requirements for real-time ptychographic image reconstruction
Kaushik Datta, Andrew Rittenbach, Dong-In Kang, et al.
Chemical Research in Toxicology
|
November 16, 2007
Metabonomic evaluation of metabolic dysregulation in rats induced by PF 376304, a novel inhibitor of phosphoinositide 3-kinase
Donald G Robertson, Kaushik Datta, Dale Wells, et al.
Regulatory Toxicology and Pharmacology : RTP
|
July 20, 2025
Strategies to reduce the use of non-human primates in the development of oncology therapeutics: CD3-bispecifics
Smitha Ps Pillai, Kaushik Datta, Petra Lutterbuese, et al.
Regulatory Toxicology and Pharmacology : RTP
|
February 21, 2021
Harmonized 3Rs-based non-mutagenic impurity qualification study designs developed using the results of an IQ consortium survey
Mayur S Mitra, Kaushik Datta, Richard Hutchinson, et al.
Clinical Pharmacology and Therapeutics
|
June 7, 2024
Beyond MABEL: An Integrative Approach to First in Human Dose Selection of Immunomodulators by the Health and Environmental Sciences Institute (HESI) Immuno-Safety Technical Committee (ITC)
Mineo Matsumoto, Joseph Ryan Polli, Suresh K Swaminathan, et al.
Regulatory Toxicology and Pharmacology : RTP
|
February 1, 2026
FIH Dose Selection Beyond MABEL: Optimizing Phase 1 clinical trial Starting Dose Whilst Protecting Patient Safety
Mineo Matsumoto, J Ryan Polli, Suresh Swaminathan, et al.
Journal of Medicinal Chemistry
|
May 14, 2010
Rational design of a topical androgen receptor antagonist for the suppression of sebum production with properties suitable for follicular delivery
Lorna H Mitchell, Theodore R Johnson, Guang Wei Lu, et al.
Toxicology
|
July 3, 2015
Importance of investigating epigenetic alterations for industry and regulators: An appraisal of current efforts by the Health and Environmental Sciences Institute
Isabelle R Miousse, Richard Currie, Kaushik Datta, et al.
Clinical Pharmacology and Therapeutics
|
September 19, 2024
Industry Perspective on First-in-Human and Clinical Pharmacology Strategies to Support Clinical Development of T-Cell Engaging Bispecific Antibodies for Cancer Therapy
Prathap Nagaraja Shastri, Nirav Shah, Martin Lechmann, et al.
Page
of 2